LLY vs SLGL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
SLGL exhibits a critical disconnect between its explosive 1-year price appreciation (+1243%) and its deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While revenue growth is exceptional at 150%, the company suffers from negative gross margins (-17.62%) and a catastrophic operating margin (-497.84%), indicating that the cost of producing its goods exceeds its sales revenue. Despite a strong liquidity position (Current Ratio 4.37) and low debt, the valuation is speculative with a Price/Book of 9.02 and a Price/Sales of 12.36. The stock is currently trading on growth momentum rather than financial viability.
Compare Another Pair
Related Comparisons
LLY vs SLGL: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Sol-Gel Technologies Ltd. (SLGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.